After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing
Avenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a reverse merger with Rallybio. The Monday morning deal comes ...
Athena Countouriotis, Avenzo Therapeutics CEO (via BioMarin) June 1, 2026 10:11 AM EDT StartupsDealsChina After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing Kyle LaHucik Biotech Correspondent Avenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a reverse merger with … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that